Triple Negative Breast Cancer
Recently Published Documents


TOTAL DOCUMENTS

11784
(FIVE YEARS 8685)

H-INDEX

121
(FIVE YEARS 66)

Life Sciences ◽  
2021 ◽  
Vol 286 ◽  
pp. 120015
Author(s):  
Yalda Khazaei-Poul ◽  
Samaneh Shojaei ◽  
Ameneh Koochaki ◽  
Hossein Ghanbarian ◽  
Samira Mohammadi-Yeganeh

2021 ◽  
Vol 46 (6) ◽  
Author(s):  
Suyanee Thongchot ◽  
Pranisa Jamjuntra ◽  
Jaturawitt Prasopsiri ◽  
Peti Thuwajit ◽  
Nunghathai Sawasdee ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yuanliang Gu ◽  
Wenjuan Wang ◽  
Xuyao Wang ◽  
Hongyi Xie ◽  
Xiaojuan Ye ◽  
...  

2021 ◽  
Vol 9 (1) ◽  
Author(s):  
Irini Skaripa-Koukelli ◽  
David Hauton ◽  
John Walsby-Tickle ◽  
Eloïse Thomas ◽  
Joshua Owen ◽  
...  

Abstract Background Triple negative breast cancer (TNBC) poses a serious clinical challenge as it is an aggressive form of the disease that lacks estrogen receptor, progesterone receptor, and ERBB2 (formerly HER2) gene amplification, which limits the treatment options. The Warburg phenotype of upregulated glycolysis in the presence of oxygen has been shown to be prevalent in TNBC. Elevated glycolysis satisfies the energy requirements of cancer cells, contributes to resistance to treatment by maintaining redox homeostasis and generating nucleotide precursors required for cell proliferation and DNA repair. Expression of the monocarboxylate transporter 1 (MCT1), which is responsible for the bidirectional transport of lactate, correlates with an aggressive phenotype and poor outcome in several cancer types, including breast cancer. In this study, 3-bromopyruvate (3BP), a lactate/pyruvate analog, was used to selectively target TNBC cells that express MCT1. Methods The cytotoxicity of 3BP was tested in MTT assays using human TNBC cell lines: BT20 (MCT1+/MCT4−), MDA-MB-23 (MCT1−/MCT4+), and BT20 in which MCT1 was knocked down (siMCT1-BT20). The metabolite profile of 3BP-treated and 3BP-untreated cells was investigated using LC-MS/MS. The extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of BT20 and MDA-MB-231 cells treated with 3BP were measured using a Seahorse XF96 extracellular flux analyzer. The impact of ionizing radiation on cell survival, alone or in combination with 3BP pre-treatment, was evaluated using clonogenic assays. Results Metabolomic analyses showed that 3BP causes inhibition of glycolysis, disturbance of redox homeostasis, decreased nucleotide synthesis, and was accompanied by a reduction in medium acidification. In addition, 3BP potentiated the cytotoxic effect of ionizing radiation, a treatment that is frequently used in the management of TNBC. Conclusions Overall, MCT1-mediated metabolic perturbation in combination with radiotherapy is shown to be a promising strategy for the treatment of glycolytic tumors such as TNBC, overcoming the selectivity challenges of targeting glycolysis with glucose analogs.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of adenylate cyclase activating polypeptide 1, encoded by ADCYAP1 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, ADCYAP1 expression was correlated with distant metastasis-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. ADCYAP1 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Jianzhao Chen ◽  
Lixia Feng ◽  
Qinghua Sheng ◽  
Lianna Li

Objective. Triple-negative breast cancer (TNBC) is an aggressive disease with highly invasive nature and poor outcomes. Due to the absence of specific treatment strategies for this tumor subgroup, patients with TNBC are treated with conventional therapeutics, frequently leading to systemic relapse. In this study, we sought to investigate apatinib combined with conventional chemotherapy regimens in treating patients with advanced TNBC concerning the efficacy, safety, expressions of tumor markers, and patient survival. Methods. This is a prospective study including 150 cases of advanced TNBC who were randomly arranged into a conventional group and combined group, with 75 cases per group. The patients in the conventional group were treated with conventional chemotherapy, and those in the combined group were treated with apatinib combined with conventional chemotherapy. The peripheral blood was collected from each patient, and carcinoembryonic antigen (CEA), carbohydrate antigen 153 (CA153), and carbohydrate antigen 125 (CA125) were determined. The expressions of nuclear proliferation antigen marker (Ki67), β-catenin, and E-cadherin were determined in the biopsy collected from each patient. Results. The objective remission rate (ORR) and disease control rate (DCR) (41.33% and 81.33%) in the combined group were notably higher than those in the conventional group (29.33% and 68.00%) ( P < 0.05 ). After treatment, the serum levels of CEA, CA153, and CA125 and the expressions of Ki67 and β-catenin were declined, but the expression of E-cadherin was increased in both groups; the combined group exhibited lower serum levels of CEA, CA153, and CA125, and the expressions of Ki67 and β-catenin were concurrent with a higher expression of E-cadherin than the conventional group ( P < 0.05 ). No significant difference was noted between the two groups regarding the occurrence of adverse reactions ( P > 0.05 ). Improved progression-free survival (PFS) was observed in the combined group compared to the conventional group ( P < 0.05 . Conclusion. These findings suggest that apatinib combined with conventional chemotherapy regimens confers a prolonged PFS for treating patients with advanced TNBC.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of mitogen-activated protein kinase kinase kinase kinase 1, encoded by MAP4K1 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, MAP4K1 expression was correlated with recurrence-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. MAP4K1 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of BRI3 binding protein, encoded by BRI3BP when comparing the primary tumors of triple negative breast cancer patients dead or alive. BRI3BP may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of G protein-coupled receptor 98, encoded by GPR98 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, GPR98 expression was correlated with distant metastasis-free survival in basal subtype breast cancer, a molecular subtype sharing significant overlap with triple negative breast cancer. GPR98 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


2021 ◽  
Author(s):  
Shahan Mamoor

We mined published microarray data (1) to understand the most significant gene expression differences in the tumors of triple negative breast cancer patients based on survival following treatment: dead or alive. We observed significant transcriptome-wide differential expression of keratin associated protein 21-1, encoded by KRTAP21-1 when comparing the primary tumors of triple negative breast cancer patients dead or alive. Importantly, KRTAP21-1 expression was correlated with recurrence-free survival inpatients with breast cancer. KRTAP21-1 may be of relevance as a biomarker or as a molecule of interest in understanding the etiology or progression of triple negative breast cancer.


Sign in / Sign up

Export Citation Format

Share Document